Not all partial dopamine D2 receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
Athan Spiros1, Robert Carr1, Hugo Geerts1,21In Silico Biosciences, Berwyn, PA, USA; 2School of Medicine, University of Pennsylvania, PA, USAAbstract: Species differences in physiology and unique active human metabolites contribute to the limited predictive value of preclinical rodent models for many...
Saved in:
Main Authors: | Athan Spiros, Robert Carr, Hugo Geerts |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2010
|
Subjects: | |
Online Access: | https://doaj.org/article/dbfab43968d34192ba8f1f3adc8a528e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Active-state model of a dopamine D2 receptor-Gαi complex stabilized by aripiprazole-type partial agonists.
by: Ralf C Kling, et al.
Published: (2014) -
Phasic dopamine reinforces distinct striatal stimulus encoding in the olfactory tubercle driving dopaminergic reward prediction
by: Lars-Lennart Oettl, et al.
Published: (2020) -
Plasticity in striatal dopamine release is governed by release-independent depression and the dopamine transporter
by: Mark D. Condon, et al.
Published: (2019) -
The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
by: Hashimoto K, et al.
Published: (2014) -
Nolz1 expression is required in dopaminergic axon guidance and striatal innervation
by: Clement Soleilhavoup, et al.
Published: (2020)